News | April 28, 2023
Yasmin and Mirena to take back seat from Bayer’s future drug strategy, says GlobalData
The news on a shift in its focus comes after the refinement of Bayer’s early innovation framework
The news on a shift in its focus comes after the refinement of Bayer’s early innovation framework
The R&D Center significantly increases Siegfried’s R&D capacity to drive further growth
This is the first time the Agency has authorized the Phase 3 clinical evaluation in the U.S of a microbiota-based live biotherapeutic based on a pooling technology
WuXi Bio provided technical services, based on the companies' versatile integrated service platforms, to support various manufacturing and process development activities of these ADC product candidates.
Alpenglow has created an end-to-end 3D spatial biology solution including patented high-throughput 3D imaging
The combination will support clients in getting their end-to-end discovery and development programs delivered.
Apremilast Tablets, 10 mg, 20 mg, and 30 mg is a generic equivalent of reference listed drug (RLD) OTEZLA of Celgene.
FDA’s NME approvals declined substantially in 2022, causing overall New Drug Application (NDA) approvals to drop
The disease is caused by a mutation in the gene encoding HMG CoA reductase, inhibiting the enzyme’s activity.
Subscribe To Our Newsletter & Stay Updated
